Micro Therapeutics' blood clotting agent to enter Europe
This article was originally published in Clinica
Executive Summary
Micro Therapeutics has CE-marked its EMBOLYX system for use in embolisation of tumours and malformations in the peripheral vascular system. This is the company's first commercial application of the product which will be distributed in Europe by Guidant.